Innovation1 Biotech Inc. Overview
Industry: Shell Companies
Sector: Financial Services
Innovation1 Biotech Inc., a drug discovery company, focuses on the development of modified schedule 1 molecules of botanical origin in the United States. Its portfolio includes five proprietary fully synthetic preclinical prodrugs addressing independent clinical indications comprising a mushroom-derived psychedelic molecule for treatment of post-traumatic stress disorder and depression; a novel cannabinoid and tree bark derived psychedelic for treatment of addiction; and three additional cannabinoid prodrugs addressing clinical indications of refractory pediatric epilepsy, hypertrophic scarring, and ocular inflammation. The company was formerly known as Gridiron BioNutrients, Inc. and changed its name to Innovation1 Biotech Inc. in March 2022. Innovation1 Biotech Inc. was founded in 2014 and is headquartered in New York, New York.
Innovation1 Biotech Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Innovation1 Biotech Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Innovation1 Biotech Inc. Competitors
Innovation1 Biotech Inc. operates in the Shell Companies industry within the Financial Services sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans